mufa 22:1 c

MUFA 22:1 c, commonly referred to as cetoleic acid or cis‑11‑docosenoic acid, is a specific long‑chain monounsaturated fatty acid characterized by a 22‑carbon backbone with one double bond in a cis configuration. It belongs to the broader class of monounsaturated fatty acids (MUFAs), which contain a single double bond in their carbon chain and are a major component of dietary fats. While the most abundant MUFA in the diet is oleic acid (C18:1), cetoleic acid represents one of the very long‑chain MUFAs that occur naturally in certain marine fish oils and some plant oils such as jojoba and avellana (Gevuina avellana) oil. Its chemical formula is C22H42O2, and as a fatty acid, it is esterified in triglycerides that make up dietary fats. In contrast to essential fatty acids like omega‑3 and omega‑6, which must be obtained from the diet, MUFAs including cetoleic acid can be synthesized endogenously from saturated fatty acids via desaturation and elongation pathways. However, the specific presence of 22:1 MUFAs in human tissues is largely diet‑dependent, reflecting the intake of foods containing this fatty acid. Although MUFA 22:1 c is present in small amounts compared with more common MUFAs such as oleic acid, it has attracted research interest due to its potential effects on lipid metabolism. Studies have explored the influence of cetoleic acid on metabolic pathways related to n‑3 fatty acids, suggesting it may enhance conversion efficiency to EPA and DHA in cell and animal models, though human data remain limited. The fatty acid is also known by several alternative names including cetoleate and 22:1n‑11, indicating its structure as a monounsaturated fatty acid with the double bond located at the n‑11 position from the methyl end of the carbon chain.

MUFA 22:1 c functions within the broader class of monounsaturated fatty acids by contributing to dietary fat composition and metabolic processes. Monounsaturated fatty acids, when replacing saturated fats in the diet, are associated with improved blood lipid profiles, including reductions in total cholesterol and potential beneficial effects on triglycerides, which are recognized factors in cardiovascular risk management. A comprehensive systematic review by USDA’s Nutrition Evidence Systematic Review project indicates strong evidence that dietary MUFAs improve intermediate cardiovascular outcomes when they replace saturated fats, including favorable changes in lipid profiles relevant to both coronary heart disease and type 2 diabetes risk. Specific research on cetoleic acid suggests unique metabolic roles. In vitro and animal studies have demonstrated that cetoleic acid may enhance the synthesis of health‑promoting long‑chain omega‑3 fatty acids such as EPA and DHA from precursors like alpha‑linolenic acid (ALA). In one study using human HepG2 liver cells and primary salmon hepatocytes, enrichment with cetoleic acid increased conversion rates of ALA to EPA and DHA by up to 40% and 12% respectively, and dietary inclusion enhanced whole‑body retention of EPA + DHA in salmon. These findings point to cetoleic acid’s potential to modulate fatty acid metabolic pathways, though translation to human health outcomes requires further investigation. Beyond metabolic effects, MUFAs broadly have been linked in controlled trials and epidemiological studies to improved insulin sensitivity and reduced plasma glucose levels compared with diets high in saturated fats. These effects may have implications for type 2 diabetes management and metabolic syndrome prevention. While cetoleic acid itself has not been studied extensively in large human clinical trials, its presence in MUFA‑rich foods that are staples of healthful dietary patterns like the Mediterranean diet suggests that it may contribute to the overall health benefits attributed to diets rich in monounsaturated fats, including potential anti‑inflammatory effects and cardiovascular benefits.

Unlike essential nutrients such as vitamins and minerals, there are no established Recommended Dietary Allowances (RDAs) or Adequate Intakes (AIs) for individual fatty acids like MUFA 22:1 c. Health authorities instead provide guidelines for total fat and fatty acid intake within the context of overall dietary patterns. General dietary recommendations typically suggest that total fat should comprise 20–35% of daily energy intake, with an emphasis on replacing saturated and trans fats with monounsaturated and polyunsaturated fats to support cardiovascular health and metabolic function. In practice, intake of MUFA 22:1 c is driven by consumption of foods that contain long‑chain monounsaturated fats, particularly fish oils from species like herring and cod liver, where cetoleic acid can constitute a notable percentage of total fatty acids. Other MUFA‑rich foods contribute indirectly by providing a spectrum of monounsaturated fats, with the majority being oleic acid. Because cetoleic acid is not essential and can be synthesized to some extent from other fatty acids through elongation pathways, there is no daily requirement per se. Instead, dietary guidance focuses on sufficient overall MUFA intake as part of a balanced dietary fat profile. Several factors influence fatty acid needs and metabolism, including age, sex, genetic factors related to fatty acid desaturase enzyme activity, physical activity levels, and the presence of metabolic conditions such as diabetes or dyslipidemia. Individuals with higher energy requirements or those following specified dietary patterns for health conditions may have differing proportions of MUFAs in their diets, but specific targets for MUFA 22:1 c intake have not been defined in clinical guidelines. Thus, ensuring adequate intake of a variety of healthy fats through whole foods is the practical recommendation.

Because MUFA 22:1 c is not classified as an essential nutrient with a defined requirement, there is no recognized deficiency syndrome attributable specifically to low intake of this fatty acid. Essential fatty acid deficiency occurs with inadequate intake of omega‑3 and omega‑6 polyunsaturated fatty acids, but monounsaturated fatty acids including cetoleic acid are not required in the diet for survival in the same way. Consequently, there are no clinical signs, laboratory markers, or diagnostic criteria specific to a deficiency of MUFA 22:1 c. General fatty acid insufficiency manifested as very low dietary fat intake can lead to signs of overall lipid deficiency such as dry skin, hair loss, poor wound healing, impaired reproductive function, and growth failure in children, but these are linked to a broad lack of dietary fats rather than a specific absence of a single MUFA. Because cetoleic acid is one of many components of dietary fats and can be synthesized endogenously from saturated fats through desaturation and elongation, the concept of deficiency for this specific fatty acid is not applicable. At‑risk populations for inadequate overall fat intake include individuals with extremely restrictive diets, malabsorption disorders such as cystic fibrosis or celiac disease, and conditions that lead to fat malabsorption (e.g., cholestatic liver diseases). In these cases, ensuring sufficient total fat intake, including MUFAs, is part of nutritional management, but there is no evidence to suggest that lack of cetoleic acid per se results in unique clinical symptoms. Laboratories do not routinely measure levels of cetoleic acid in blood as part of standard fatty acid panels, and no optimal reference ranges have been established.

Although the specific content of MUFA 22:1 c (cetoleic acid) in foods is not widely reported in standard nutrient databases, certain foods are known to contain higher proportions of very‑long‑chain monounsaturated fatty acids. Marine fish oils from species such as herring and cod liver have been documented to contain significant proportions of cetoleic acid within their fatty acid profiles, where it may constitute up to 12% of total fatty acids in cod liver oil and similar levels in herring oil. However, the exact amount in these foods varies with species, diet, and processing. In addition to fish oil sources, select plant oils like jojoba and avellana (Chilean hazelnut) oil have been noted for their content of cetoleic acid, though these are less common in typical diets. Since most dietary MUFAs are in the form of oleic acid (C18:1), foods high in total MUFAs indirectly support intake of long‑chain MUFAs including 22:1 isomers. Typical MUFA‑rich foods include: • Extra‑virgin olive oil (rich in oleic acid, with MUFA content ~70% of total fat) — a staple of healthful dietary patterns. • Avocado and avocado oil — high in monounsaturated fats. • Nuts such as almonds, macadamias, and hazelnuts — provide significant MUFA content. • Canola oil and high‑oleic sunflower oils — refined oils with elevated MUFAs. • Peanut butter and peanuts — contain notable MUFAs. • Fish species such as salmon, mackerel, trout, and sardines contribute MUFA along with beneficial omega‑3 fats. The following table provides a list of 15 foods high in monounsaturated fats (primarily oleic acid) which serve as good dietary sources of total MUFAs. Exact MUFA 22:1 c amounts are not available for all foods but these foods support overall MUFA intake.

Fatty acids including MUFA 22:1 c are absorbed in the small intestine after dietary fats are emulsified by bile salts and hydrolyzed by pancreatic lipases. The resulting free fatty acids and monoglycerides form micelles, which facilitate passive diffusion across enterocyte membranes. Inside intestinal cells, fatty acids are re‑esterified into triglycerides and incorporated into chylomicrons for lymphatic transport into the circulation. The efficiency of this process for monounsaturated fats is similar to that for other dietary fats, with overall absorption rates often exceeding 90% for long‑chain fatty acids when consumed in a typical diet. Factors enhancing absorption include co‑ingestion with other dietary fats, which stimulates bile secretion, and adequate pancreatic enzyme activity. Conversely, conditions that impair fat digestion—such as pancreatic insufficiency, bile acid deficiency due to liver or biliary disease, or small intestinal dysbiosis—can reduce absorption. High fiber intake in the same meal may modestly reduce fat absorption due to binding of bile acids and altered micelle formation. Because cetoleic acid is a component of triglycerides within food lipids, it follows these general absorption pathways, and there is no evidence of unique transport mechanisms for this specific MUFA variant. Once absorbed, MUFAs are incorporated within lipoproteins and transported to tissues for energy or storage. Long‑chain MUFAs may undergo elongation or beta‑oxidation, contributing to energy metabolism. The bioavailability of individual MUFAs can differ based on food matrix, degree of processing, and concomitant nutrient intake, but overall monounsaturated fats are considered readily absorbed and metabolically accessible.

There are currently no dietary supplements specifically formulated to provide MUFA 22:1 c (cetoleic acid) alone, and no authoritative guidance recommending supplementation of this specific fatty acid. Supplements that provide broader fatty acid support typically focus on essential polyunsaturated fatty acids such as omega‑3s (EPA and DHA), which have well‑established intake recommendations. The NIH Office of Dietary Supplements provides extensive guidance on omega‑3 fatty acids and their health effects, but monounsaturated fatty acids are generally not the focus of supplement recommendations because they are abundant in whole foods and not considered essential nutrients requiring supplementation. For most individuals, increasing intake of MUFA‑rich foods such as olive oil, avocados, nuts, and fatty fish is a practical way to support lipid profile health and overall dietary fat quality. People considering supplements for specific health conditions should consult a healthcare provider, as dietary supplements can interact with medications and may not provide consistent benefits. Supplements marketed for heart health often contain fish oil or algal oil high in EPA and DHA rather than specific MUFAs. It is important to note that the NIH does not have a fact sheet on MUFA 22:1 c, and general dietary fat guidelines emphasize total fat balance rather than isolated fatty acid supplementation. In summary, supplementation targeted at cetoleic acid is not routinely recommended. Instead, prioritizing a balanced dietary pattern rich in healthy fats, including monounsaturated and polyunsaturated fats, meets broader nutritional needs. Individuals with conditions affecting fat absorption or metabolism should discuss tailored approaches with a registered dietitian or medical professional.

There is no established tolerable upper intake level (UL) for MUFA 22:1 c, and dietary fats including monounsaturated fats have not been linked to specific toxicity at usual intake levels from foods. However, exceptionally high intake of total fats can contribute to excessive caloric consumption and weight gain, which is associated with increased risk of metabolic disorders such as insulin resistance, type 2 diabetes, and cardiovascular disease. Fat intake should therefore be balanced within overall energy needs. For cetoleic acid specifically, some chemical sources suggest that, like its positional isomer erucic acid, it may have toxic effects at high exposure levels in isolated chemical forms, but this is not based on typical dietary consumption. Erucic acid at high levels has been associated with cardiac lipidosis in animal studies; however, cetoleic acid’s safety profile in humans has not been extensively characterized separate from general MUFAs in dietary fats. Thus, focusing on whole foods rather than isolated fatty acids minimizes any theoretical toxicity risk and supports overall dietary quality.

Monounsaturated fatty acids such as those found in MUFA‑rich foods do not typically have direct drug interactions the way some micronutrients (e.g., vitamin K with warfarin) do, but dietary fats can influence the absorption and pharmacokinetics of certain medications. High‑fat meals may increase the absorption of lipophilic drugs, altering their bioavailability. Individuals taking medications with narrow therapeutic windows should discuss with healthcare providers how meal composition might affect drug efficacy. Additionally, supplements containing high doses of fish oils or omega‑3 fatty acids (which also provide fats) may interact with anticoagulant medications such as warfarin and antiplatelet drugs by modestly affecting bleeding risk, though monounsaturated fats alone are not typically implicated. Always consult a healthcare provider before combining high‑dose fatty acid supplements with prescription medications.

Common Forms: fish oil, marine oil supplements

Typical Doses: Not applicable for isolated 22:1

When to Take: With meals containing fat

Best Form: triglyceride form